Table 1.
Clinicopathological Characteristics and SOX17 Methylation Status in Human Lung Cancer
| Clinical Parameter | Number of Patients | SOX17 Methylation Status | P Value* | |
|---|---|---|---|---|
| Methylated | Unmethylated | |||
| n=53 (60.2%) | n=35 (39.8%) | |||
| Age (years) | ||||
| <65 | 60 | 37 (61.7%) | 23 (38.3%) | 0.6863 |
| ≥65 | 28 | 16 (57.1%) | 12 (42.9%) | |
| Sex | ||||
| Male | 60 | 30 (50.0%) | 30 (50.0%) | 0.0084 |
| Female | 28 | 23 (82.1%) | 5 (17.9%) | |
| Smoking | ||||
| Negative | 3 | 1 (33.3%) | 2 (67.6%) | 0.9001 |
| Positive | 40 | 22 (55.0%) | 18 (45.0%) | |
| Tumor type | ||||
| Squamous cell | 34 | 20 (58.8%) | 14 (41.2%) | 0.9908 |
| Adenocarcinoma | 46 | 27 (58.7%) | 19 (41.3%) | |
| Tumor differentiation | ||||
| Low | 38 | 29 (76.3%) | 9 (23.7%) | 0.0133 |
| Middle | 38 | 20 (52.6%) | 18 (47.4%) | |
| High | 12 | 4 (33.3%) | 8 (66.7%) | |
| Tumor stage | ||||
| I | 36 | 15 (41.7%) | 21 (58.3%) | 0.9618 |
| II | 25 | 10 (40.0%) | 15 (60.0%) | |
| III | 25 | 9 (36.0%) | 16 (64.0%) | |
| IV | 2 | 1 (50.0%) | 1 (50.0%) | |
*
P values were obtained from χ2 tests; P<0.05 indicates significant difference.